Summary & Overview
HCPCS C9016: Injection, triptorelin extended release, 3.75 mg
HCPCS Level II code C9016 denotes the injection of triptorelin extended release, 3.75 mg, a long-acting gonadotropin-releasing hormone agonist used for medical hormone suppression in conditions managed in outpatient specialty clinics. This code matters nationally because it captures billing for a specialty therapeutic agent administered in ambulatory settings and influences coverage, reimbursement, and care pathways for patients requiring hormonal suppression.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the medication and the common settings where the injection is delivered, alongside payer coverage considerations. The publication outlines national benchmarks and policy-relevant items such as coverage criteria and coding practice implications, and it highlights where data are available or not.
This resource provides clinicians, billing staff, and policy analysts with clear information about what HCPCS Level II code C9016 represents, the applicable service environment, and the types of payer policies and benchmarks typically relevant to billing and coverage decisions for extended-release triptorelin injections.
Billing Code Overview
HCPCS Level II code C9016 represents Injection, triptorelin extended release, 3.75 mg. The service involves administration of an extended-release formulation of triptorelin, a gonadotropin-releasing hormone (GnRH) agonist used in hormone suppression therapies. The service type is therapeutic injection. The typical site of service is outpatient clinic or physician office, including oncology or urology specialty clinics, and ambulatory care settings where intramuscular or subcutaneous injections are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult receiving specialty-administered, intramuscular depot therapy with triptorelin extended release 3.75 mg for hormone-dependent conditions such as advanced prostate cancer or endometriosis. The medication is supplied and billed under HCPCS Level II code C9016. The clinical workflow begins with an outpatient oncology, urology, or gynecology visit where the clinician documents the indication, informed consent, and treatment plan. The patient is escorted to an infusion or procedure room in an ambulatory clinic, hospital outpatient department, or physician office where a licensed clinician (physician, advanced practice provider, or registered nurse) verifies identity and allergies, prepares the syringe, and administers the intramuscular depot injection, typically into the gluteal muscle. Post-injection observation for a short period is performed for adverse effects. Documentation includes the drug name, dose, lot number, NDC if recorded, site of injection, date/time, supervising clinician, and any immediate reactions. Billing uses C9016 for the product; relevant claim modifiers (for example 51 when multiple procedures are reported on the same day) are appended per payer rules. Typical sites of service are: ambulatory clinic, physician office, hospital outpatient department, or long‑term care facility when administered under supervision.
Coding Specifications
| Modifier | Description | When to Use |
|---|